Related references
Note: Only part of the references are listed.Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants
Judith M. Gottwein et al.
GASTROENTEROLOGY (2018)
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad et al.
HEPATOLOGY (2018)
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study
R. D'Ambrosio et al.
JOURNAL OF HEPATOLOGY (2018)
Significant changes of HCV patient characteristics over time in the era of direct antiviral agent therapy - are all HCV subpopulations treated similarly? - Results from the German hepatitis C Cohort
S. Christensen et al.
JOURNAL OF HEPATOLOGY (2018)
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
Christophe Hezode et al.
JOURNAL OF HEPATOLOGY (2018)
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection
D. Wyles et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Recommendations on Treatment of Hepatitis C 2018
JOURNAL OF HEPATOLOGY (2018)
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti et al.
JOURNAL OF HEPATOLOGY (2018)
SAFETY AND EFFICACY OF STATIN MANAGEMENT DURING GLECAPREVIR/PIBRENTASVIR TREATMENT FOR CHRONIC HEPATITIS C
Paul Kwo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects
Matthew P. Kosloski et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study
Chih-Wei Lin et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
Teresa I. Ng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Glecaprevir and Pibrentasvir for 12 Weeks for Hepatitis C Virus Genotype 1 Infection and Prior Direct-Acting Antiviral Treatment
Fred Poordad et al.
HEPATOLOGY (2017)
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects
Chih-Wei Lin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection: an integrated analysis
J. -F. Dufour et al.
JOURNAL OF HEPATOLOGY (2017)
Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis
E. Gane et al.
JOURNAL OF HEPATOLOGY (2017)
Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1-6 and chronic kidney disease: an integrated analysis
S. Pol et al.
JOURNAL OF HEPATOLOGY (2017)
The PREVAIL Study: intensive models of HCV care for people who inject drugs
A. H. Litwin et al.
JOURNAL OF HEPATOLOGY (2017)
Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials
P. Krishnan et al.
JOURNAL OF HEPATOLOGY (2017)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study
J. Rockstroh et al.
JOURNAL OF HEPATOLOGY (2017)
MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection
N. Reau et al.
JOURNAL OF HEPATOLOGY (2017)
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study
Chih-Wei Lin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns et al.
LANCET INFECTIOUS DISEASES (2017)
Direct-acting antiviral agents for HCV infection affecting people who inject drugs
Jason Grebely et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Edward Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Elimination of HCV as a public health concern among people who inject drugs by 2030-What will it take to get there?
Jason Grebely et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2017)
Hepatitis C virus infection
Michael P. Manns et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
Teresa I. Ng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study
Tess Petersen et al.
HEPATOLOGY INTERNATIONAL (2016)
Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir
Kerry Townsend et al.
AIDS (2016)
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
Edward Gane et al.
GASTROENTEROLOGY (2016)
Hepatitis C Drugs: Is Next Generation the Last Generation?
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2016)
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF NEXT GENERATION DIRECT ACTING ANTIVIRALS ABT-493 AND ABT-530 IN SUBJECTS WITH HEPATIC IMPAIRMENT
M. P. Kosloski et al.
JOURNAL OF HEPATOLOGY (2016)
The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control
Jens Bukh
JOURNAL OF HEPATOLOGY (2016)
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
Zobair M. Younossi et al.
MEDICINE (2016)
Hepatitis C Virus Therapeutic Development: In Pursuit of Perfectovir
Gregory J. Dore et al.
CLINICAL INFECTIOUS DISEASES (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
J. J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion
Adeel A. Butt et al.
JAMA INTERNAL MEDICINE (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
The natural history of compensated HCV-related cirrhosis: A prospective long-term study
Eduardo Vilar Gomez et al.
JOURNAL OF HEPATOLOGY (2013)
Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels
Jason Grebely et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Major Challenges Limiting Liver Transplantation in the United States
J. A. Wertheim et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Share Paper
